Loading clinical trials...
Loading clinical trials...
TD-1607, administered intravenously as multiple ascending doses, will be investigated in healthy subjects to assess its tolerability, safety, and pharmacokinetics.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Theravance Biopharma
NCT00018044 · Mycobacterium Infections
NCT06631287 · Long COVID, Sars-CoV-2 Infection, and more
NCT00344188 · Leishmaniasis, Skin Diseases, Parasitic, and more
NCT07286370 · Salmonella Infections
NCT07297966 · Recurrent Respiratory Tract Infections
PPD, Phase 1 Clinic
Austin, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions